Developing Country Vaccine Markets Presentation to 2015 DCVMN Meeting Amie Batson Chief Strategy Officer, PATH October 2015 PATH/Eric Becker
Agenda What is the “developing country” vaccine market? Globally financed developing country vaccine market – Demand Supply Financing Opportunities and challenges for the future 2
Changing Demand Landscape - 2006 Source: UNICEF public data 3
Changing Demand Landscape - 2007 Source: UNICEF public data 4
Changing Demand Landscape - 2008 Source: UNICEF public data 5
Changing Demand Landscape - 2009 Source: UNICEF public data 6
Changing Demand Landscape - 2010 Source: UNICEF public data 7
Changing Demand Landscape - 2011 Rapid adoption of PCV Source: UNICEF public data 8
Changing Demand Landscape - 2012 Source: UNICEF public data 9
Changing Demand Landscape - 2013 Source: UNICEF public data 10
Changing Demand Landscape - 2014 Source: UNICEF public data 11
New Product Combinations – DTP Family 1998-2014 Source: UNICEF public data 12
New Product Combinations – Measles Family 2014-2030 Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only 13
Increasing Value (UNICEF Contracts 2001-14) Source: UNICEF public data 14
New Markets (Gavi Graduation 2015-30) Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only. 15
New Markets (Gavi Graduation 2015-30) Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only. 16
New Markets (Gavi Graduation 2015-30) Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only. 17
New Markets (Gavi Graduation 2015-30) Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only. 18
New Products in the Pipeline Source: WHO public data; PATH and partners’ analysis, July 2015 19
Examples of Manufacturers Leading the Way Chengdu Institute of Biological Products (CDIBP) Japanese encephalitis Serum Institute of India Ltd. Meningitis A 20
DCVM diversity Market Driver Product Portfolio/ Production Scale Emerging MNCs New Entrants Parastatal Global Actors Local Gatekeepers Niche Largest Product Portfolio/ Production Scale Privately Held State-owned Market Driver
DCVM diversity Market Driver Product Portfolio/ Production Scale Parastatal Global Actors Local Providers State-owned Market Driver Emerging MNCs New Entrants Privately Held Niche Largest Product Portfolio/ Production Scale
DCVM diversity Product Portfolio/ Production Scale Local Providers New Parastatal Global Actors Local Providers Emerging MNCs New Entrants State-owned Privately Held Niche Largest Market Driver Product Portfolio/ Production Scale Not exhaustive
Opportunities and Challenges for the Future Regulatory Approval/PQ GAVI Graduation Access to high margin markets Shift to combination vaccine Advantage for Regional Products? Market Knowledge Lower Cost Creative partnership
twitter.com/PATHtweets twitter.com/AmieBatson Connect with Me www.path.org twitter.com/PATHtweets twitter.com/AmieBatson 25